Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

Nichols, Russell M; Macpherson, Lisa; Patel, Dipak R; Yeh, Wendy W; Peppercorn, Amanda

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

Nichols, Russell M; Macpherson, Lisa; Patel, Dipak R; Yeh, Wendy W; Peppercorn, Amanda.

Afiliação

Nichols RM; Eli Lilly and Company, Indianapolis, IN, USA. rnichols@lilly.com.
Macpherson L; Eli Lilly and Company, Indianapolis, IN, USA.
Patel DR; Eli Lilly and Company, Indianapolis, IN, USA.
Yeh WW; Vir Biotechnology, Inc., San Francisco, CA, USA.
Peppercorn A; GSK, Cambridge, MA, USA.

Infect Dis Ther ; 13(2): 401-411, 2024 Feb.

Article em En | MEDLINE | ID: mdl-38291279

Palavras-chave

Bamlanivimab; Etesevimab; SARS-CoV-2; Sotrovimab; Viral load; mAb

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2024 Tipo de documento: Article